A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients†
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867011524323704832 |
|---|---|
| author | Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme |
| author_facet | Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme |
| collection | Wiley Open Access |
| contents | A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients† Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme The Journal of Pathology AbstractBreast cancer includes a group of neoplasms originating from mammary gland epithelial cells caused by a variety of genetic alterations, with different responses to treatments and outcomes. In clinical practice, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression guides the distinction between luminal A (ER+, PR+, HER2−), luminal B (ER+, PR+, HER2+/−), and triple‐negative (ER−, PR−, HER2−), each with a distinct biological behavior and clinical and therapeutic implications. Approximately 11% of breast cancers are diagnosed in young premenopausal women aged 20–49 years. Patient‐derived xenografts (PDXs) offer a powerful solution to integrate personalized medicine and novel therapeutic agents. Dr Belletti's group recently developed a PDX biobank composed of 26 PDX lines highly enriched in luminal A and B and young premenopausal breast cancer patients. The bank faithfully recapitulates the characteristics of the original tumors. A major focus of their research was to exploit these PDXs to assess the resistance to CDK4/6 inhibitors (CDK4/6i), which are critical in managing advanced luminal breast cancers. Their effort addresses a significant gap in existing PDX models, which are limited for these patient subgroups, thereby enabling deeper insights into tumor biology and therapeutic responses in these understudied populations. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6418 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/path.6418 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_path_6418 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients† Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme The Journal of Pathology A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients† Paola Defilippi Francesca Nigrelli Pietro Arina Daniela Taverna Vincenzo Salemme The Journal of Pathology AbstractBreast cancer includes a group of neoplasms originating from mammary gland epithelial cells caused by a variety of genetic alterations, with different responses to treatments and outcomes. In clinical practice, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression guides the distinction between luminal A (ER+, PR+, HER2−), luminal B (ER+, PR+, HER2+/−), and triple‐negative (ER−, PR−, HER2−), each with a distinct biological behavior and clinical and therapeutic implications. Approximately 11% of breast cancers are diagnosed in young premenopausal women aged 20–49 years. Patient‐derived xenografts (PDXs) offer a powerful solution to integrate personalized medicine and novel therapeutic agents. Dr Belletti's group recently developed a PDX biobank composed of 26 PDX lines highly enriched in luminal A and B and young premenopausal breast cancer patients. The bank faithfully recapitulates the characteristics of the original tumors. A major focus of their research was to exploit these PDXs to assess the resistance to CDK4/6 inhibitors (CDK4/6i), which are critical in managing advanced luminal breast cancers. Their effort addresses a significant gap in existing PDX models, which are limited for these patient subgroups, thereby enabling deeper insights into tumor biology and therapeutic responses in these understudied populations. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6418 http://creativecommons.org/licenses/by/4.0/ |
| title | A breast cancer PDX collection enriched in luminal (ER+) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients† |
| topic | The Journal of Pathology |
| url | https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6418 |